|
|
||||||||
Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, USA
Reprint requests to: J. Throck Watson, Michigan State University, 401 Biochemistry Bldg., MSU Campus, East Lansing, MI 48824, USA; e-mail: watsonj{at}msu.edu.; fax: (517) 353-9334.
(RECEIVED January 8, 2003; ACCEPTED April 16, 2003)
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.0301403.
1 Some absorbance detectors, such as ours, cannot simultaneously monitor both a UV and a visible wavelength due to second order interference effects. Upper UV absorbance data were therefore included as an alternative to visible wavelength absorbance detection. ![]()
| Abstract |
|---|
|
|
|---|
Keywords: DABMI; prompt fragmentation; MALDI
| Introduction |
|---|
|
|
|---|
In working with the hydrophobic maleimide 4-dimethylaminophenylazophenyl-4-maleimide (DABMI) derivative of cysteine-containing peptides, we have discovered a unique and useful property, evident under specific UV-MALDI conditions, that allows for the identification of these peptides through a mass spectral pattern of ions arising from prompt fragmentation of the DABMI moiety. A valuable feature of DABMI (common to all maleimides), for analyses done in the presence of disulfide bonds, is its high specificity and reactivity with sulfhydryl groups at mildly acidic pH; this provides efficient sulfhydryl labeling, while minimizing disulfide bond scrambling. Because the maleimide only reacts with reduced cysteine residues (free thiols), the presence of a DABMI-labeled peptide in a processed sample is indicative of free cysteine in the original peptide (or in the protein, if processing involved digestion).
DABMI has been used primarily in fluorescence resonance energy transfer studies. The synthesis and use of DABMI as a tool for the selective isolation of cysteine-containing peptides was first described by Chang et al (1983). In that work, both DABMI and N-[4-(4-dimethylaminophenylazo)phenyl]iodoacetamide (DABIA) were used to label free thiol-containing peptides and proteins, such that after digestion with endoproteases, the resulting peptides could be separated by RP-HPLC and selectively detected by monitoring their absorbance of visible light. Here, we describe a powerful tool for tracking, isolating, and identifying cysteinyl peptides on the basis of the capacity to detect DABMI-labeled peptides by absorbance at wavelengths not absorbed by unlabeled peptides, combined with the ability to recognize DABMI-labeled peptides by their signature MALDI mass spectrum.
| Materials and methods |
|---|
|
|
|---|
-cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid, 2,5-dihydroxybenzoic acid (DHB), 2-mercaptobenzothiazole (MBT), and bumetanide were obtained from Sigma-Aldrich. Insulin-like growth Factor I residues 5770 (IGF; H2N-ALLETYCATPAKSE-COOH ) was purchased from American Peptide Company. The 6-Amino-2-mercaptobenzothiazole (AMBT) and 2-mercaptobenzoxazole (MBO) were purchased from TCI. Tyrosine hydroxylase (TH) was donated by Prof. Donald M. Kuhn of Wayne State University. All other materials were of the highest purity available.
DABMI labeling of cysteine-containing peptides
IGF was dissolved in a 6-M guanidine HCl/0.1 M Citrate buffer (pH 5.0), (Gua/Cit5) that had been saturated with acetonitrile saturated with DABMI (
290-µM DABMI in 33% ACN/67% Gua/Cit5 [v/v]). Peptides derived from peptic digestion of TH were derivatized by adding 165 µL of the above solution to 330 µL of the digestion mixture (which was in 10 mM HCl). The reaction was allowed to take place for 1 h in the dark at room temperature.
Absorbance spectra of DABMI and derivatives
Absorbance spectra of DABMI, DABMI-IGF, and base-hydrolyzed DABMI-IGF (hydDABMI-IGF) were obtained by infusing the microbore flow cell of a properly calibrated Waters 2487 dual wavelength HPLC absorbance detector with a solution (
30 µM) of the analyte that had been prepurified by HPLC and was dissolved in 65/35 water/acetonitrile containing 0.1% trifluoroacetic acid (v/v). An absorbance spectrum was then obtained in scan mode from 190 to 700 nm, subtracting the absorbance spectrum of pure solvent as background.
Analysis by MALDI-MS
Unless otherwise indicated, samples were prepared by spotting 0.5 µL analyte + matrix onto a gold-plated or stainless-steel well-less sample plate with CHCA as the matrix, using the modified thin-layer technique of Cadene and Chait (2000). MALDI mass spectra were acquired on a Voyager DE-STR time-of-flight (TOF) mass spectrometer (Perkin-Elmer Biosystems Inc.) equipped with a 337-nm nitrogen laser. For measurements made in linear (or reflector) mode, the accelerating voltage was set to 20,000 V (20,000 V) with grid voltage at 95% (76%), guide wire at 0.05% (0.02%), and extraction delay time at 150 nsec (150 nsec). Time-of-flight to mass conversion was achieved with the use of external standards of bradykinin (monoisotopic calculated mass for MH+ = 1060.57 Da; average mass for MH+ = 1061.22 Da), and bovine pancreatic insulin (average calculated mass for MH+ = 5734.56 Da; average calculated mass to charge ratio for [M+2H]2+ = 2867.78).
| Results and Discussion |
|---|
|
|
|---|
|
Data describing the optimal wavelengths for monitoring DABMI-derivatized peptides were not available previously, and were therefore gathered by obtaining absorbance spectra of DABMI-IGF and base-hydrolyzed DABMI-IGF (hydDABMI-IGF) to determine upper UV1 and visible wavelength
max values (Table 1). When maleimide-peptide derivatives are exposed to basic conditions, the maleimide moiety can undergo ring-opening hydrolysis or cyclization with an adjacent amine to yield a cross-linked product (Wu and Yarbrough 1976; Ishii and Lehrer 1986). (We have not observed the latter.) Thus, absorbance data on hydDABMI-IGF are included. The same prompt fragmentation products arise from base-hydrolyzed DABMI derivatives as from derivatives containing an intact maleimide ring.
Tracking DABMI-labeled peptides by HPLC is already useful, but now cysteine-containing peptides can be recognized readily by their prompt fragmentation pattern in a MALDI mass spectrum when CHCA is used as matrix. Figure 2
shows an HPLC chromatogram of a peptic digest of native TH (a 498-residue protein with seven free cysteine residues) that was subsequently labeled with DABMI. (Pepsin is not a specific protease [Keil 1992], causing each cysteine residue to be distributed among 45 different peptic peptides.) Figure 3
is a MALDI mass spectrum of a chromatographic fraction collected at the time indicated in Figure 2
, but during an analogous chromatographic run of the same sample (except
4.5-fold more material injected). On the basis of prompt fragmentation patterns, it is readily evident in the MALDI mass spectrum (Fig. 3
) that there are four different cysteine-containing DABMI-labeled peptides present in the sample; their MH+ ions are represented by peaks at m/z 1060.8, m/z 1385.0, m/z 1509.0, and m/z 2004.4. Two examples are highlighted (see insets in Fig. 3
); the peak at m/z 1385.0 represents the monoisotopic version of a DABMI-labeled MH+, whereas the peak at m/z 1253.0 represents the corresponding [MH - 132]+. The peak at m/z 2004.4 represents the monoisotopic version of another MH+, whereas the peak at m/z 1872.3 represents its corresponding [MH - 132]+ (the less abundant [MH - 120]+ and [MH - 14]+ fragment ions are also represented in the mass spectrum). (As verification that certain peaks represent fragmentation products of DABMI-labeled peptides, a MALDI mass spectrum could be taken of the sample cocrystallized with sinapinic acid instead of CHCA; in such a case, fragmentation products will not be observed.) Other peaks in Figure 3
represent MH+ of coeluting peptides that lack cysteine; for example, none of these other peaks is accompanied by a fragment occurring 132 u lower in the spectrum. If it were to coelute with a peptide of interest, the DABMI reagent would not interfere in the mass spectrum because its mass (320 Da) is below the low-m/z cutoff.
|
|
|
Conclusions
The methodology described here allows the recognition of DABMI-labeled cysteine-containing peptides based on UV or visible light absorbance and by the unique fragmentation pattern produced by the DABMI moiety during analysis by MALDI-MS. Once the MH+ ion of the DABMI derivative of a cysteine-containing peptide has been recognized through its characteristic mass spectral pattern, a simple mass-mapping procedure frequently provides the identity of the DABMI-labeled peptide. The facile recognition of cysteine-containing peptides imparted by this methodology can be particularly useful when mass-mapping peptides in a digest carried out with proteases lacking significant specificity (e.g., pepsin). During analysis of DABMI-labeled peptides, it is readily obvious when a cysteine-containing peptide is represented in the MALDI mass spectrum. When the ion represented in the mass spectrum is known to contain a cysteine residue, the number of candidate mass-matched peptides becomes greatly reducedoften allowing for identification of the peptide. Under more specific proteolytic conditions, verification of cysteinyl peptides, by way of the MALDI mass spectrum, can add a substantial degree of certainty to a mass-mapping assignment.
|
| Acknowledgments |
|---|
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
| References |
|---|
|
|
|---|
Cadene, M. and Chait, B.T. 2000. A robust, detergent-friendly method for mass spectrometric analysis of integral membrane proteins. Anal. Chem. 72: 56555658.[Medline]
Chang, J.Y., Knecht, R., and Braun, D.G. 1983. A new method for the selective isolation of cysteine-containing peptides. Biochem. J. 211: 163171.[Medline]
Ishii, Y.and Lehrer, S.S. 1986. Effects of the state of the succinimido-ring on the fluorescence and structural properties of pyrene maleimide-labeled
-tropomyosin. Biophys. J. 50: 7589.
Keil, B. 1992. Specificity of proteolysis, pp. ix, 336. Springer-Verlag, Berlin.
Lavine, G. and Allison, J. 1999. Evaluation of bumetanide as a matrix for prompt fragmentation matrix-assisted laser desorption/ionization and demonstration of prompt fragmentation/post-source decay matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 34: 741748.[CrossRef][Medline]
Moran, L.K., Gutteridge, J.M., and Quinlan, G.J. 2001. Thiols in cellular redox signalling and control. Curr. Med. Chem. 8: 763772.[Medline]
Romero-Isart, N. and Vasak, M. 2002. Advances in the structure and chemistry of metallothioneins. J. Inorg. Biochem. 88: 388396.[CrossRef][Medline]
Viner, R.I., Williams, T.D., and Schoneich, C. 1999. Peroxynitrite modification of protein thiols: Oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase. Biochemistry 38: 1240812415.[CrossRef][Medline]
Wilcox, D.E., Schenk, A.D., Feldman, B.M., and Xu, Y. 2001. Oxidation of zinc-binding cysteine residues in transcription factor proteins. Antioxid. Redox. Signal 3: 549564.[CrossRef][Medline]
Wu, C.W. and Yarbrough, L.R. 1976. N-(1-pyrene)maleimide: A fluorescent cross-linking reagent. Biochemistry 15: 28632868.[CrossRef][Medline]
Xu, N., Huang, Z.H., Watson, J.T., and Gage, D.A. 1997. Mercaptobenzothiazoles: A new class of matrices for laser desorption ionization mass spectrometry. J. Am. Soc. Mass Spectrom 8: 116124.[CrossRef]
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |